DLX2蛋白在胃癌的表達(dá)與臨床意義
發(fā)布時(shí)間：2018-09-06 10:04
【摘要】：背景 胃癌是最常見(jiàn)的惡性消化道腫瘤之一,發(fā)病率及死亡率均位于前列。對(duì)于很多國(guó)家,尤其是發(fā)展中國(guó)家而言是十分重要的公共衛(wèi)生問(wèn)題。我國(guó)是胃癌高發(fā)地區(qū)之一。據(jù)統(tǒng)計(jì),我國(guó)胃癌發(fā)病占全世界42%左右,農(nóng)村發(fā)病率超過(guò)城市。然而,胃癌的病因及發(fā)病機(jī)制仍不明確。因此,研究其發(fā)生、發(fā)展、浸潤(rùn)、轉(zhuǎn)移相關(guān)的分子調(diào)控機(jī)制對(duì)了解疾病、促進(jìn)治療具有重要意義。 同源盒轉(zhuǎn)錄因子基因2(DLX2, distal-less homeobox2)是DLX基因家族中的一員。已有大量研究證實(shí)DLX2對(duì)于胚胎發(fā)育有及其重要的作用,但關(guān)于它在腫瘤中的作用在近些年才被提出。已有研究證明在血液系統(tǒng)腫瘤、膠質(zhì)瘤、乳腺癌等惡性腫瘤中均有DLX2異常表達(dá)。在胃癌中僅有一項(xiàng)研究,認(rèn)為DLX2的表達(dá)與腫瘤分期有關(guān)。 本研究運(yùn)用大樣本量的組織芯片及免疫組織化學(xué)技術(shù)對(duì)胃癌組織中DLX2蛋白的表達(dá)進(jìn)行測(cè)定,并結(jié)合臨床病理資料探索其臨床意義,為未來(lái)進(jìn)一步的研究提供方向。 目的 檢測(cè)DLX2蛋白在胃癌組織芯片中的表達(dá)水平并分析其臨床意義。 方法 收集浙江大學(xué)附屬邵逸夫醫(yī)院腫瘤外科1997年至2011年胃癌術(shù)后組織標(biāo)本472例。同時(shí)整理相關(guān)臨床信息及隨訪資料。參照文獻(xiàn)中的制作方法,將組織蠟塊制成組織芯片。然后對(duì)芯片進(jìn)行免疫組化染色,請(qǐng)兩位有經(jīng)驗(yàn)的病理科醫(yī)師讀片,觀察DLX2蛋白的表達(dá)情況。最終我們匯總得到262例有完整信息的病例。統(tǒng)計(jì)分析這些病例胃癌組織中DLX2蛋白的表達(dá)與臨床意義。 結(jié)果 1.列聯(lián)分析提示DLX2蛋白的表達(dá)與Her-2蛋白表達(dá)有明顯的相關(guān)性,Her-2陰性組中DLX2的表達(dá)較陽(yáng)性組高。(p=0.004)。 2. Kaplan Meier生存分析及COX比例風(fēng)險(xiǎn)模型提示DLX2對(duì)胃癌患者生存無(wú)顯著性影響,但DLX2高表達(dá)患者的中位生存期較低表達(dá)患者降低。 結(jié)論 DLX2蛋白在胃癌組織中有表達(dá),且與Her-2蛋白表達(dá)明顯相關(guān),但對(duì)生存無(wú)顯著影響。
[Abstract]:Background gastric cancer is one of the most common malignant digestive tract tumors, morbidity and mortality are in the forefront. It is a very important public health problem for many countries, especially developing countries. China is one of the regions with high incidence of gastric cancer. According to statistics, the incidence of gastric cancer in China accounts for about 42% of the world. However, the etiology and pathogenesis of gastric cancer are still unclear. Therefore, it is important to study the molecular regulatory mechanisms related to its occurrence, development, infiltration and metastasis in order to understand disease and promote treatment. Homologous cassette transcription factor 2 (DLX2, distal-less homeobox2) is a member of DLX gene family. A large number of studies have confirmed that DLX2 plays an important role in embryonic development, but its role in tumor has only been proposed in recent years. Abnormal expression of DLX2 has been demonstrated in hematological tumors, gliomas, breast cancer and other malignancies. In only one study of gastric cancer, the expression of DLX2 was associated with tumor staging. In this study, the expression of DLX2 protein in gastric cancer tissues was determined by tissue microarray and immunohistochemical technique, and its clinical significance was explored in combination with clinicopathological data, which provided a direction for further research in the future. Objective to detect the expression of DLX2 protein in gastric cancer tissue microarray and analyze its clinical significance. Methods 472 specimens of gastric cancer were collected from 1997 to 2011 in Shaw Hospital of Zhejiang University. At the same time, the clinical information and follow-up data were collected. The tissue wax block was made into tissue chip according to the method in the literature. Then the microarray was stained by immunohistochemistry and two experienced pathologists were asked to read the film and observe the expression of DLX2 protein. Finally, we gathered 262 cases with complete information. The expression and clinical significance of DLX2 protein in gastric cancer tissues were analyzed statistically. Result 1. The DLX2 expression in Her-2 negative group was significantly higher than that in positive group (p0. 004). 2. Kaplan Meier survival analysis and COX proportional risk model suggested that DLX2 had no significant effect on the survival of gastric cancer patients, but the median survival time of patients with high DLX2 expression was lower than that of patients with low DLX2 expression. Conclusion the expression of DLX2 protein in gastric cancer tissues was significantly related to the expression of Her-2 protein, but had no significant effect on survival.
【學(xué)位授予單位】：浙江大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2015
【分類號(hào)】：R735.2
本文編號(hào)：2226004
[Abstract]:Background gastric cancer is one of the most common malignant digestive tract tumors, morbidity and mortality are in the forefront. It is a very important public health problem for many countries, especially developing countries. China is one of the regions with high incidence of gastric cancer. According to statistics, the incidence of gastric cancer in China accounts for about 42% of the world. However, the etiology and pathogenesis of gastric cancer are still unclear. Therefore, it is important to study the molecular regulatory mechanisms related to its occurrence, development, infiltration and metastasis in order to understand disease and promote treatment. Homologous cassette transcription factor 2 (DLX2, distal-less homeobox2) is a member of DLX gene family. A large number of studies have confirmed that DLX2 plays an important role in embryonic development, but its role in tumor has only been proposed in recent years. Abnormal expression of DLX2 has been demonstrated in hematological tumors, gliomas, breast cancer and other malignancies. In only one study of gastric cancer, the expression of DLX2 was associated with tumor staging. In this study, the expression of DLX2 protein in gastric cancer tissues was determined by tissue microarray and immunohistochemical technique, and its clinical significance was explored in combination with clinicopathological data, which provided a direction for further research in the future. Objective to detect the expression of DLX2 protein in gastric cancer tissue microarray and analyze its clinical significance. Methods 472 specimens of gastric cancer were collected from 1997 to 2011 in Shaw Hospital of Zhejiang University. At the same time, the clinical information and follow-up data were collected. The tissue wax block was made into tissue chip according to the method in the literature. Then the microarray was stained by immunohistochemistry and two experienced pathologists were asked to read the film and observe the expression of DLX2 protein. Finally, we gathered 262 cases with complete information. The expression and clinical significance of DLX2 protein in gastric cancer tissues were analyzed statistically. Result 1. The DLX2 expression in Her-2 negative group was significantly higher than that in positive group (p0. 004). 2. Kaplan Meier survival analysis and COX proportional risk model suggested that DLX2 had no significant effect on the survival of gastric cancer patients, but the median survival time of patients with high DLX2 expression was lower than that of patients with low DLX2 expression. Conclusion the expression of DLX2 protein in gastric cancer tissues was significantly related to the expression of Her-2 protein, but had no significant effect on survival.
【學(xué)位授予單位】：浙江大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2015
【分類號(hào)】：R735.2
【參考文獻(xiàn)】
相關(guān)期刊論文 前6條
1 于滿,楊毅,牛瑞芳,史玉榮,魏熙胤,張霖,王德發(fā);同源異型盒基因BP1在乳腺癌組織中的表達(dá)及其臨床意義[J];癌癥;2004年07期
2 宋永春;傅四東;溫小鵬;馬振華;黨誠(chéng)學(xué);;BP1基因和Cyclin D1基因在乳腺癌組織中的表達(dá)及意義[J];癌癥;2007年07期
3 陸萌;席曉薇;;同源異型盒DLX基因調(diào)控婦科惡性腫瘤機(jī)制的探討[J];現(xiàn)代婦產(chǎn)科進(jìn)展;2008年08期
4 周小鴿,張勁松,張小平,張野,Kristian Sandvej,Stephen J Hamilton-Dutoit;組織芯片[J];中華病理學(xué)雜志;2002年01期
5 陳萬(wàn)青;張思維;鄭榮壽;曾紅梅;鄒小農(nóng);趙平;吳良有;李光琳;赫捷;;中國(guó)2009年惡性腫瘤發(fā)病和死亡分析[J];中國(guó)腫瘤;2013年01期
6 Peng Tang;Hua Huang;Jiang Chang;Gong-Fang Zhao;Ming-Liang Lu;Yan Wang;;Increased expression of DLX2 correlates with advanced stage of gastric adenocarcinoma[J];World Journal of Gastroenterology;2013年17期
，本文編號(hào)：2226004
本文鏈接：http://sikaile.net/yixuelunwen/zlx/2226004.html
最近更新
教材專著
